A firm foundation for future growth
- Leading supplier of both generic injectable and non-injectable products in the US
- Leading market position in MENA (second largest pharmaceutical company by sales) and a growing presence in Europe
- Trusted partner known for our commitment to quality and reliability of supply
- Broad portfolio of high-quality products
- Agile supply chain, flexible manufacturing and leading technical capabilities
Highlights
An increasingly diverse portfolio and pipeline
- Growing presence in specialty and complex products, which offer less competition and more potential for future margin growth
- Focus on higher-value therapeutic areas such as cardiovascular, central nervous system (CNS) and oncology
- Annual investment in R&D to ensure we are consistently
launching new products across our markets - Strong track record of value-creating partnerships, strategic
acquisitions and geographic expansion, to enhance pipeline
and access to new markets
Highlights
A strong balance sheet and robust cash generation
- Good cash flow generation, with $608 million operating cash flow in 2023
- Highly disciplined approach to cash management and acquisitions
- Strong balance sheet that provides financial flexibility to
support future growth, and low leverage of 1.2x net debt/
core EBITDA
Highlights
A proven track record of delivery for shareholders
- A clear vision for growth
- Group revenue compound annual growth rate (CAGR) of 7% and core EBITDA CAGR of 8% since 2018
- Total shareholder return of 76% over the last ten years
- Progressively increasing dividend
Highlights
All figures for year ending 31 December 2023.
Latest news
Related content